A "Wish List" Comes True at Matrix
Executive SummaryThe FDA has been getting tougher on cancer drugs. Lately, it's been asking drugmakers to provide proof not just that their therapies can shrink tumors, but that doing so actually benefits patients--in a way that matters to those patients, not just their doctors. Matrix Pharmaceutical Inc. thinks it got that proof, by asking patients and physicians to choose, before they began participating in its clinical studies, the clinical endpoints they would most like to realize from treatment with IntraDose, a gel-based formulation of the well-known chemotherapeutic agent cisplatin.
You may also be interested in...
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.
The FDA has readied plans for hastened emergency-use approvals of coronavirus test kits after an infected US citizen returned to Washington State from Wuhan province in China. See what the FDA’s Megan McSeveney said about it here.
Despite obvious similarities in the contentious reviews of Sarepta’s Vyondys 53 and its predecessor Exondys 51, drug developers should focus on the differences between the two reviews.